1[1]Conway DS,Pearce LA,Chin BS,Hart RG,Lip GY.Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation:relationnship to stroke risk factors[J].Circulation,2002,106(15):1962-7.
2[2]Conway DS,Heeringa J,Van Der Kuip DA,Chin BS,Hofman A,Witteman JC,Lip Gy.Atrial fibrllation and the prothrombotic state in the elderly:the Rotterdamstudy[J].Stroke,2003,34(2):413-7.
3[3]Li-Saw-Hee FL,Blann AD,Lip GY.A cross-sectinal and diurnal study of thrombogenesis among patients with chronic atrial fibrillation[J].Am Coll Cardiol,2000,35(7):1926-31.
4[4]Goldsmith IR,Foo LS,Blann AD,Lip GY.Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation immediately following percutaneous balloon mitral valvuloplasty[J].Clin Cardiol,2000,23(8):587-90.
5[5]Li-Saw-Hee FL,Blann AD,Edmunds E,Gibbs CR,Lip GY.Effect of acute exercise on the raised plasma fibrinogen,soluble P-selectin and von Willebrand factor levels in chronic atrial fibrillation[J].Clin Cardiol,2001,24(5):409-14.
6[6]Li-Saw-Hee Fl,Blann AD,Gurney D,Lip GY.Plasma von Willebrand factor,fibrinogen and soluble P-selectin levels in paroxysmal,persistent and permanent atrial fibrillation.Effects of cardioversion and return of left atrial function[J].Eur Heart J,2001,22(18):1741-7.
7[7]Mondillo S,Sabatini L,Agricola E,Ammaturo T,Guerrini F,Barbati R,Pastore M,Fineschi D,Nami R.Correlation between left atrial size,prothrombotic state and markers of endothelial dysfunction in patients with long chronic nonrheumatic atrial fibrillation[J].Int J Cardiol,2000.
8[8]Kozuka K,Kohriyama T,Nomura E,Ikeda J,Kajikawa H,Nakamura S.Endothelial markers and adhesion molecules in acute ischemic stroke-sequential change and differences in stroke subtype[J].Atherosclerosis,2002,161(1):161-8.
9[9]Blann AD,Lip GY.Beevers DG,McCollum CN.Soluble P-selectin in atherosclerosis:a comparison with endothelial cell and platelet markers[J].Thromb Haemost,1997,77(6):1077-80.
10[10]Go AS,Hylek EM,Phillips KA,Borowsky LH,Henault LE,Chang Y,Selectinby JV,Singer DE.Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation:the Anticoagulation and Risk Factors in Atrialfibrillation(ATRIA)study[J].Circulation,2000,102(1):11-3.
3Muramatsu B, Shimura T. Incidence o5 cereoral thromboembolice infarction associated with paroxysmal and persistent or sistent or permanent atrialfibrillation[J].JACC, 2000,35 (supplA): 103-105.
4Mousa SA, Abdel-Razeq HN. Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?Cardiovasc Drug Rev[J]. 2005 Winter; 23(4): 331-344.
5Taylor FC, Cohen H, gbrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with nonrheumatic atrial fibrillation[J].BMJ. 2001, 322(7282): 321-326.
6Ederhy S, Cohen i. Optimising stroke prevention in nonvalvular atrial fibrillation. Expert opinion on pharmacotherapy, 2006, 17 (15): 2079-2094.
7Connolly SJ. Preventing stoke in patients with atrial fibrillation; Current treatments and newconeepts[J]. Am Heart J, 2003, 115 (3) :418 -423.
8Knoderer CA, Knoderer HM, Turrentine M, et al. Lepirudin anticoagulation for heparin induced throm bocytopenia afte: cardiac surgery in a pediatric patient [J]. Pharmacotherapy, 2006,26 ( 5 ) : 709 - 712.
9Keeling D ,Davidson S,W arson H, et al. The managem ent of heparin - induced thrombocytopenia[J]. Br J Haematol, 2006,135 (2) :269.
10Evans HC,Perry CM,Faulds D. Ximelagatran'Melagatran:Are view of its use in lhe prevention of venous thromboem holism in orthopaedic surgery[J]. Drugs,2004,64(6) :649 - 678.
